Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT03062332 |
Other study ID # |
TGMOBAD2017 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 16, 2020 |
Est. completion date |
November 2022 |
Study information
Verified date |
August 2021 |
Source |
First Affiliated Hospital Xi'an Jiaotong University |
Contact |
Xiancang Ma, professor |
Phone |
13002951782 |
Email |
maxiancang[@]163.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Background: The gut microbiome is emerging as an important factor in regulating mental health
yet it remains unclear what the target should be for psychiatric treatment. Investigators aim
at elucidating the complement of the gut microbiome community for individuals with Major
Depressive disorder (MDD) and Bipolar disorder (BD) relative to controls, and test for
relationships with symptoms.
Methods: Investigators prospect to recruit subjects including patients and controls amount to
240. All subjects will be collected for blood and stool samples,assessed by clinical scales.
Finally, analyzing the correlation among the metabolon in blood, microbiota in stool and
clinical scales to obtain the possible interaction between diseases and gut microbiota.
Description:
Background: MDD (Major Depressive disorder) and BD (Bipolar disorder), whose specific
pathogenesis is still unclear, are both a multi-factorial disease being caused by biological,
psychological and social factors. Accumulating evidence suggests that gut microbiota play an
important role in brain functions and in the pathogenesis of neuropsychiatric diseases, such
as autism, anxiety, as well as depression. No study has thus far compared the human gut
microbiota among BD, MDD and the healthy control (HC). The aim of this study is to compare
the composition of fecal microbiota among BD, MDD and HC. Furthermore, investigators aim at
identifying direct correlations between human fecal microbiota (as a proxy for gut
microbiota) and symptoms.
Methods:
1. Investigators aim at recruiting human subjects in total 240, which including mania
episode of bipolar disorder (40), depressive episode of bipolar disorder (40), mixed
episode of bipolar disorder (40), first episode of major depressive disorder (40),
recurrent episode of major depressive disorder (40), and healthy control (40). All
patients, diagnosed according to the research criteria of the 10th revision of the
International Statistical Classification of Diseases and Related Health Problems
(ICD-10), come from The First Affiliated Hospital of Xi'an Jiaotong University and
controls are healthy volunteers.
2. Collecting blood and stool samples, evaluating clinical scales including
Montgomery-Asberg Depression Scale (MADRS), Young Mania Rating Scale (YMRS), Hamilton
Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Measurement And Treatment
Research To Improve Cognition In Schizophrenia (MATRICS) Consensus Cognitive Battery
(MCCB), Clinical Global Impression (CGI) are all finished in first day after threshold.
3. Measure the metabolon in blood such as S-CFA, and gut microbiota.
4. Using Statistical Program for Social Sciences (SPSS) to compare general and clinical
data among groups and analyze the correlation between the microbiota and symptoms.